Badi El Osta, MD, FACP
-
RoleMedical Oncology
-
Specialty
-
Research Program
-
Practicing Since2016
Background
Board certified in medical oncology and palliative medicine, Badi El Osta, MD, FACP, specializes in the prevention and treatment of head and neck, and lung cancers. Since joining the Emory faculty in 2016, he has been actively involved in patient care and clinical research, as well as in the education of Emory University oncology fellows and medical residents at the Atlanta VA Medical Center. Dr. El Osta is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
Dr. El Osta serves as the clinical lead for Hematology and Oncology of the VA Southeast Network, where he also serves as the chair of the Cancer Committee and the chair of the Atlanta VA Healthcare System Cancer Committee. He is a clinical member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. He also serves as a member of the Biomedical Committee of the Institutional Review Board at Emory University.
Dr. El Osta received his MD from Saint Joseph's University School of Medicine in Beirut, Lebanon. He completed his residency at Good Samaritan Hospital in Cincinnati, Ohio. Thereafter, he completed three fellowships: Hematology/Oncology at the Medical College of Georgia in Augusta, Georgia; Investigational Cancer Therapeutics (phase 1 clinical trials) and Palliative Care at the University of Texas MD Anderson Cancer Center in Houston, Texas.
Titles & Roles
-
Associate Professor, Department of Hematology and Medical OncologyEmory University School of Medicine
Education & Training
Education
- Fellowship, Hematology/Oncology, 2016Medical College of Georgia
- Fellowship, 2013MD Anderson Cancer Center
- Fellowship, 2007MD Anderson Cancer Center
- Residency, Internal Medicine, 2005Good Samaritan Hospital - OH
- Medical Education, MD, 1998American University of Beirut, Lebanon
Board Certifications
- Medical OncologyAmerican Board of Internal Medicine, 2016Hospice and Palliative MedicineAmerican Board of Internal Medicine, 2012
Professional Memberships
Dr. El Osta holds professional memberships with American Society of Clinical Oncology, Cancer Therapy Evaluation Program, Eastern Cooperative Oncology Group – American College of Radiology Imaging Network, Association of VA Hematology/Oncology, American College of Physicians, International Association for the Study of Lung Cancer and European Society of Medical Oncology.
Research
Dr. El Osta’s research focuses on clinical trials to mitigate resistance to immunotherapy. With collaboration with VA investigators, his work focuses on increasing access to molecular sequencing and clinical trials for veterans with lung cancer. He collaborates with experts in artificial intelligence to predict benefit, improve outcomes and resources utilization and prevent unnecessary toxicity to veterans with lung cancer. He is the lead site investigator for the VA Lung Precision Oncology Program and senior investigator for ECOG-ACRIN trials at the Atlanta VA Medical Center.
-
-
PhaseIII
-
ConditionsRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
-
-
-
PhaseII
-
ConditionsMetastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
-
LocationEmory University Hospital Midtown, Winship Cancer Institute, Grady Health System
-
Publications
Title/Journal Authors Publication Date MET alterations in advanced non-small cell lung cancer.
Current problems in cancer
GCL Chagas, AR Rangel, B El Osta 04/01/2024 JTO clinical and research reports
KE Beckermann, CM Bestvina, B El Osta, RE Sanborn, H Borghaei, PE Lammers, G Selvaggi, JG Whisenant, E Heimann-Nichols, L Berry, CY Hsu, Y Shyr, L Horn, H Wakelee 02/01/2024 Is It Prime Time for Perioperative Therapy in Patients With Resectable Non-Small-Cell Lung Cancer?
JCO oncology practice
B El Osta, O Ababneh 09/01/2023 KRAS G12C mutation: from undruggable target to potentially agnostic biomarker.
Translational lung cancer research
B El Osta 06/30/2023 Clinical lung cancer
BE Osta, J Carlisle, C Steuer, S Pakkala, T Leal, M Dhodapkar, Y Liu, Z Chen, T Owonikoko, S Ramalingam 11/01/2022 Novel targeted therapies for advanced non-small lung cancer.
Seminars in oncology
O Abughanimeh, A Kaur, B El Osta, AK Ganti 04/01/2022 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
B El Osta, M Behera, S Kim, LD Berry, G Sica, RN Pillai, TK Owonikoko, MG Kris, BE Johnson, DJ Kwiatkowski, LM Sholl, DL Aisner, PA Bunn, FR Khuri, SS Ramalingam 05/01/2019 First Report of Parkinsonism Associated With Indoximod, an Immune-Modulating Agent.
Journal of global oncology
M Floyd, B El Osta, SC Tang 09/01/2018 Acute blepharitis: an unusual complication of zoledronic acid.
International journal of rheumatic diseases
LE Osta, BE Osta 04/01/2017 Cancer discovery
DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, S Piha-Paul, V Subbiah, B Kee, AM Tsimberidou, D Fogelman, J Bellido, I Shureiqi, H Huang, J Atkins, G Tarcic, N Sommer, R Lanman, F Meric-Bernstam, S Kopetz 12/01/2016 Awards
- ASCO Foundation Pain Merit Award, 2006
- ASCO Foundation Oncology Merit Award, 2007
Ratings & Reviews
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.